Donald J. Hayden, Jr.
President @ Bristol-Myers Squibb
Donald J. Hayden, Jr. is a Series B investor at Bristol-Myers Squibb focused on Health Care and Biotechnology. Don Hayden is a Senior Advisor to Prospect Venture Partners. Mr. Hayden brings to Prospect the experiences and perspective resulting from a highly-successful 25 year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development.Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics.Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Donald J. Hayden, Jr. invests in
Stages Donald J. Hayden, Jr. invests in
Countries Donald J. Hayden, Jr. invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Medical Device 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nora Therapeutics
|
Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine.Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF)procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. | $18M / Series B / Apr 17, 2014 |
Co-Investors
About Bristol-Myers Squibb
Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.
Bristol-Myers Squibb Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John damonti
Foundation President
|
|||
Chris Boerner
Executive Vice President, Chief Commercialization Officer
|
|||
Debra Boyko-DeBrito
Director Content Management Solutions
|
|||
|
Donald J. Hayden, Jr.
President
|
|||
Doug Bassett
SVP Informatics & Predictive Sciences
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Donald J. Hayden, Jr. invest in?
Donald J. Hayden, Jr. invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Donald J. Hayden, Jr.?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Donald J. Hayden, Jr. last invest?
The most recent investment recorded for Donald J. Hayden, Jr. closed in Apr 2014. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
